Apollo Hospitals Enterprise (APOLLOHOSP)₹8,550+1.42%Hospital
In the Jun 2026 quarter (consolidated), Apollo Hospitals Enterprise reported sales of ₹7,059 Cr, up 20.6% from Jun 2025, and net profit of ₹611 Cr, up 38.4% year on year. For the year to Mar 2026, sales were ₹25,306 Cr and net profit ₹2,004 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,861 | 4,861 | 4,956 | 5,099 | 5,603 | 5,538 | 5,609 | 5,855 | 6,320 | 6,491 | 6,626 | 7,059 |
| Expenses | 4,204 | 4,226 | 4,294 | 4,397 | 4,761 | 4,751 | 4,811 | 4,976 | 5,345 | 5,493 | 5,583 | 5,939 |
| Operating Profit | 629 | 615 | 641 | 676 | 817 | 764 | 771 | 853 | 943 | 966 | 1,012 | 1,093 |
| OPM % | 13.1% | 13.1% | 13.1% | 13.1% | 15.1% | 14.1% | 14.1% | 15.0% | 15.1% | 15.1% | 15.1% | 16.1% |
| Other Income | 26.02 | 29.02 | 37.04 | 49.04 | 44.04 | 69.01 | 72.02 | 54.01 | 61.08 | 48.02 | 54.01 | 62.05 |
| Interest | 111 | 113 | 119 | 116 | 118 | 110 | 115 | 108 | 110 | 113 | 119 | 120 |
| Depreciation | 163 | 167 | 190 | 177 | 184 | 185 | 211 | 214 | 218 | 219 | 224 | 235 |
| Profit before tax | 380 | 364 | 368 | 431 | 558 | 537 | 517 | 584 | 676 | 683 | 724 | 801 |
| Tax % | 34.0% | 30.0% | 30.0% | 27.0% | 29.0% | 29.0% | 20.0% | 24.0% | 27.0% | 24.0% | 24.0% | 24.0% |
| Exceptional items | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −14.97 | 0.00 | 0.00 |
| Net Profit | 249 | 254 | 258 | 317 | 397 | 380 | 415 | 441 | 495 | 517 | 551 | 611 |
| EPS (Rs) | 16.19 | 17.05 | 17.66 | 21.22 | 26.33 | 25.86 | 27.07 | 30.09 | 33.20 | 34.94 | 36.82 | 40.40 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,164 | 7,278 | 8,260 | 9,632 | 11,281 | 10,593 | 14,698 | 16,642 | 19,104 | 21,858 | 25,306 | 26,497 |
| Expenses | 5,452 | 6,499 | 7,425 | 8,526 | 9,631 | 9,391 | 12,445 | 14,512 | 16,628 | 18,719 | 21,406 | 22,359 |
| Operating Profit | 685 | 735 | 803 | 1,071 | 1,594 | 1,141 | 2,191 | 2,068 | 2,398 | 3,037 | 3,783 | 4,014 |
| OPM % | 11.1% | 10.1% | 10.1% | 11.1% | 14.0% | 11.1% | 15.0% | 12.1% | 13.1% | 14.1% | 15.1% | 15.2% |
| Other Income | 92.07 | 60.03 | 24.04 | 26.03 | 222 | 103 | 369 | 75.07 | 123 | 222 | 207 | 225 |
| Interest | 180 | 258 | 296 | 328 | 535 | 450 | 380 | 382 | 450 | 459 | 451 | 463 |
| Depreciation | 264 | 313 | 358 | 396 | 619 | 572 | 600 | 614 | 686 | 757 | 874 | 894 |
| Profit before tax | 333 | 223 | 171 | 374 | 661 | 221 | 1,580 | 1,147 | 1,382 | 2,042 | 2,668 | 2,883 |
| Tax % | 29.0% | 41.0% | 65.0% | 47.0% | 34.0% | 38.0% | 30.0% | 22.0% | 32.0% | 26.0% | 25.0% | — |
| Exceptional items | 7.98 | −1.99 | −2.99 | 0.00 | 129 | 39.92 | 219 | 8.99 | 23.93 | 89.81 | 72.90 | −14.97 |
| Net Profit | 235 | 131 | 60.08 | 200 | 433 | 137 | 1,109 | 845 | 937 | 1,507 | 2,004 | 2,174 |
| EPS (Rs) | 16.98 | 15.89 | 8.43 | 16.95 | 32.71 | 10.47 | 73.40 | 56.98 | 62.52 | 100.46 | 135.06 | 145.36 |
| Dividend payout % | 35.0% | 37.9% | 59.0% | 35.0% | 18.0% | 29.0% | 16.0% | 26.0% | 26.0% | 13.0% | 15.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70.22 | 70.30 | 70.26 | 70.28 | 70.24 | 70.23 | 72.21 | 72.22 | 72.32 | 72.29 | 72.24 | 72.22 |
| Reserves | 3,098 | 3,256 | 3,238 | 3,175 | 3,259 | 3,265 | 4,526 | 5,539 | 6,116 | 6,854 | 8,120 | 9,397 |
| Borrowings | 1,999 | 2,844 | 3,135 | 3,438 | 3,683 | 3,605 | 4,176 | 4,081 | 4,344 | 5,347 | 7,892 | 8,524 |
| Other Liabilities | 1,298 | 1,192 | 1,664 | 1,919 | 2,156 | 4,352 | 2,618 | 3,567 | 3,897 | 4,473 | 4,580 | 4,203 |
| Total Liabilities | 6,465 | 7,361 | 8,107 | 8,603 | 9,169 | 11,292 | 11,392 | 13,260 | 14,430 | 16,746 | 20,665 | 22,196 |
| Fixed Assets | 3,247 | 3,996 | 4,593 | 4,776 | 4,983 | 7,434 | 6,776 | 8,294 | 8,528 | 9,661 | 10,999 | 12,274 |
| CWIP | 533 | 562 | 347 | 712 | 823 | 236 | 234 | 46.04 | 610 | 874 | 922 | 1,032 |
| Investments | 311 | 353 | 407 | 353 | 463 | 435 | 1,345 | 817 | 575 | 988 | 2,492 | 2,184 |
| Other Assets | 2,374 | 2,450 | 2,760 | 2,762 | 2,901 | 3,187 | 3,037 | 4,103 | 4,716 | 5,223 | 6,252 | 6,706 |
| Inventories | 350 | 406 | 467 | 567 | 585 | 739 | 250 | 432 | 390 | 461 | 482 | 543 |
| Trade receivables | 606 | 607 | 749 | 821 | 1,019 | 1,023 | 1,325 | 1,758 | 2,225 | 2,504 | 3,006 | 3,472 |
| Cash & equivalents | 376 | 378 | 522 | 415 | 346 | 465 | 721 | 921 | 773 | 932 | 1,356 | 1,113 |
| Total Assets | 6,465 | 7,361 | 8,107 | 8,603 | 9,169 | 11,292 | 11,392 | 13,260 | 14,430 | 16,746 | 20,665 | 22,196 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 470 | 597 | 622 | 537 | 904 | 1,292 | 1,263 | 1,694 | 1,376 | 1,918 | 2,133 | 2,853 |
| Cash from investing activity | −761 | −891 | −1,156 | −407 | −714 | −290 | −884 | −749 | −861 | −1,543 | −3,397 | −2,152 |
| Cash from financing activity | 392 | 330 | 477 | −108 | −215 | −909 | −340 | −791 | −633 | −311 | 1,318 | −478 |
| Net cash flow | 103 | 38.99 | −52.03 | 24.02 | −19.99 | 94.09 | 43.99 | 158 | −113 | 72.01 | 73.07 | 233 |
| Capex | 869 | 1,018 | 674 | 622 | 680 | 514 | 297 | 658 | 1,130 | 1,139 | 1,715 | 1,965 |
| Free cash flow | −396 | −394 | −46.04 | −84.12 | 233 | 783 | 985 | 1,046 | 252 | 786 | 439 | 926 |
| CFO / OP % | 77.0% | 108.0% | 103.0% | 83.0% | 103.0% | 100.0% | 108.0% | 87.0% | 85.0% | 100.0% | 86.0% | 92.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 42 | 35 | 37 | 36 | 38 | 32 | 45 | 43 | 48 | 47 | 50 | 49 |
| Inventory days | 50 | 49 | 47 | 51 | 46 | 49 | 16 | 21 | 17 | 17 | 16 | 15 |
| Days payable | 59 | 66 | 51 | 55 | 56 | 60 | 74 | 79 | 82 | 88 | 72 | 63 |
| Cash conversion cycle | 34 | 19 | 34 | 33 | 29 | 22 | −12 | −14 | −16 | −23 | −6 | 3 |
| Working capital days | 25 | 17 | 28 | 9 | −2 | −7 | −3 | 6 | 0 | −18 | −5 | −24 |
| ROCE % | 12.0% | 9.0% | 8.0% | 7.0% | 10.0% | 14.0% | 8.0% | 17.0% | 14.0% | 15.0% | 17.0% | 17.0% |
For the Jun 2026 quarter, Apollo Hospitals Enterprise reported sales of ₹7,059 Cr, up 20.6% year on year and net profit of ₹611 Cr, up 38.4% year on year. The operating margin was 16.1%.
Apollo Hospitals Enterprise's sales for the year to Mar 2026 were ₹25,306 Cr; over the last twelve months they were ₹26,497 Cr.
Net profit for the year to Mar 2026 was ₹2,004 Cr, and ₹2,174 Cr over the last twelve months. Earnings per share over the same trailing period were ₹145.36.
Apollo Hospitals Enterprise reported borrowings of ₹8,524 Cr at Mar 2026, against cash and equivalents of ₹1,113 Cr.
Cash from operations was ₹2,853 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹926 Cr.